Manufactures generic formulations exported to the US, UK and Australia through owned subsidiaries.
Manufactures generic formulations exported to the US, UK and Australia through owned subsidiaries.
Makes the drugs in its own plants and sells them through its own marketing subsidiaries in each regulated market, so it deals directly with pharmacy chains and distributors rather than through a third-party marketer. India is the production base, and sales are mostly overseas.
In one line: A generics manufacturer exporting via owned distribution subsidiaries.
Moat: narrow (regulatory licence). FDA/MHRA-approved plants plus owned marketing subsidiaries in regulated markets support steady exports.
Headquarters: Mumbai, India · Founded: 1982 · Employees: 1,685
Size Marksans Pharma (MARKSANS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.43B, the 493rd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹294.50 on 18 Nov 2026.
Performance Over six months the shares gained 35.5%, against -14.6% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 24.2% over the last twelve months (peer median +11.3%); the operating margin is 20.0% (peer median 10.2%).
Valuation It trades at 23.2× forward earnings against a peer median of 16.0× (5th most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.5 points below its cost of capital (19.0% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹33.9B | ₹29.5B | ₹26.2B | ₹21.8B | ₹18.5B |
| Revenue growth | — | +13% | +20% | +18% | — |
| Gross profit | ₹13.9B | ₹9.45B | ₹8.65B | ₹7.02B | ₹5.96B |
| EBITDA | ₹7.83B | ₹6.00B | ₹5.30B | ₹4.61B | ₹3.52B |
| Net income | ₹5.60B | ₹4.18B | ₹3.81B | ₹3.14B | ₹2.66B |
| Free cash flow | n/a | ₹3.51B | ₹652M | ₹473M | ₹1.88B |
| Capital expenditure | n/a | ₹1.31B | ₹1.73B | ₹2.09B | ₹536M |
| Total debt | ₹4.65B | ₹3.43B | ₹3.22B | ₹2.44B | ₹1.23B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Marksans Pharma MARKSANS.NS | $1.43B | +36% | +24% | 20% | 23.2× | 31.0% |
| Aurobindo Pharma AUROPHARMA.NS | $11.0B | +19% | +14% | 15% | 22.3× | 21.1% |
| Caplin Point Laboratories CAPLIPOINT.NS | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% |
| Lupin LUPIN.NS | $9.67B | -14% | +24% | 24% | 21.0× | 8.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MARKSANS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.8% | -3.7% | 10th highest of 20 |
| 6-month return | +35.5% | -14.6% | 2nd highest of 20 |
| Distance from 52-week high | -16.1% | -40.8% | highest of 20 |
| Revenue growth (TTM) | +24.2% | +11.3% | 4th highest of 19 |
| Operating margin | 20.0% | 10.2% | 2nd highest of 19 |
| Forward P/E | 23.2× | 16.0× | 5th most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 31.0% | -4.9% | 2nd most demanding of 10 |
| Growth delivered (Del g) | +16.6% | +12.7% | 5th highest of 10 |
| Hurdle (Req g minus delivered) | +14.5 pp | -8.0 pp | 2nd most demanding of 10 |
| ROIC minus cost of capital | -0.5 pp | -1.8 pp | 10th highest of 20 |
| EV / EBITDA | 16.2× | 13.7× | 3rd cheapest of 5 |
| Net debt / EBITDA | -0.8× | 0.3× | 2nd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 23.2× | 31.0% | +16.6% |
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | n/a | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 7.9× | -18.1% | +7.0% |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | n/a | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 9.9× | -6.4% | +12.7% |
| Xiamen Kingdomway 002626.SZ | China | $1.45B | -3% | -3% | 11% | 27.2× | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 12.1× | -9.6% | +4.6% |
| Corona Remedies CORONA.NS | India | $1.48B | +27% | +17% | 18% | 58.9× | 36.3% | +16.6% |
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | n/a | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | n/a | n/a | n/a |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | n/a | n/a | n/a |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | n/a | n/a | n/a |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 13.0× | 3.9% | +22.8% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | n/a | -4.9% | +0.2% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 16.0× | -6.1% | +1.9% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | n/a | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | n/a | 10.2% | +18.1% |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 48.6× | 25.9% | +23.1% |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 174.4× | n/a | n/a |